JP2024500512A5 - - Google Patents
Info
- Publication number
- JP2024500512A5 JP2024500512A5 JP2023539061A JP2023539061A JP2024500512A5 JP 2024500512 A5 JP2024500512 A5 JP 2024500512A5 JP 2023539061 A JP2023539061 A JP 2023539061A JP 2023539061 A JP2023539061 A JP 2023539061A JP 2024500512 A5 JP2024500512 A5 JP 2024500512A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence shown
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011544445 | 2020-12-23 | ||
| CN202011544445.8 | 2020-12-23 | ||
| PCT/CN2021/140449 WO2022135467A1 (zh) | 2020-12-23 | 2021-12-22 | 抗b7-h3抗体及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500512A JP2024500512A (ja) | 2024-01-09 |
| JP2024500512A5 true JP2024500512A5 (cg-RX-API-DMAC7.html) | 2025-01-07 |
| JP7871265B2 JP7871265B2 (ja) | 2026-06-08 |
Family
ID=82157408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539061A Active JP7871265B2 (ja) | 2020-12-23 | 2021-12-22 | 抗b7-h3抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240043540A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4269435A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7871265B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230124959A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117098548A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021407023B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203257A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022135467A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119948063A (zh) * | 2022-06-23 | 2025-05-06 | 信达生物制药(苏州)有限公司 | 结合egfr和b7-h3的双特异性抗体 |
| WO2024007129A1 (zh) * | 2022-07-04 | 2024-01-11 | 英诺湖医药(杭州)有限公司 | 人源化的b7h3抗体或其抗原结合片段 |
| CN119925631A (zh) * | 2023-11-03 | 2025-05-06 | 信达生物制药(苏州)有限公司 | 靶向b7-h3的抗体-药物偶联物及其用途 |
| WO2025131054A1 (en) * | 2023-12-22 | 2025-06-26 | Innovent Biologics (Suzhou) Co., Ltd. | Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| DK2542256T3 (da) * | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2703486B1 (en) * | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| KR102485788B1 (ko) | 2014-08-27 | 2023-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 항체, 조성물 및 용도 |
| US10865245B2 (en) * | 2014-12-23 | 2020-12-15 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| RS61828B1 (sr) * | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
| CN109843927B (zh) * | 2017-03-06 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体、其抗原结合片段及其医药用途 |
| TW201909926A (zh) * | 2017-08-04 | 2019-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | B7h3抗體-藥物偶聯物及其醫藥用途 |
| WO2020094120A1 (zh) * | 2018-11-09 | 2020-05-14 | 上海复旦张江生物医药股份有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
| CN109851673B (zh) * | 2019-01-22 | 2023-07-25 | 苏州旭光科星抗体生物科技有限公司 | 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒 |
| CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
-
2021
- 2021-12-22 CA CA3203257A patent/CA3203257A1/en active Pending
- 2021-12-22 JP JP2023539061A patent/JP7871265B2/ja active Active
- 2021-12-22 CN CN202180086116.XA patent/CN117098548A/zh active Pending
- 2021-12-22 AU AU2021407023A patent/AU2021407023B2/en active Active
- 2021-12-22 EP EP21909462.0A patent/EP4269435A4/en active Pending
- 2021-12-22 WO PCT/CN2021/140449 patent/WO2022135467A1/zh not_active Ceased
- 2021-12-22 US US18/258,576 patent/US20240043540A1/en active Pending
- 2021-12-22 KR KR1020237023796A patent/KR20230124959A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7412521B2 (ja) | Cd47に対するヒト化及びキメラモノクローナル抗体 | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| JP2022533538A5 (cg-RX-API-DMAC7.html) | ||
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP2020522280A5 (cg-RX-API-DMAC7.html) | ||
| EP2928919A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2020522281A5 (cg-RX-API-DMAC7.html) | ||
| EP3092252B1 (en) | Antibody targeting cell surface deposited complement protein c3d and use thereof | |
| JP2024540148A5 (cg-RX-API-DMAC7.html) | ||
| KR20220167331A (ko) | 항-flt3 항체 및 조성물 | |
| CN117500833A (zh) | 一种双抗组合及其应用 | |
| WO2021098822A1 (zh) | 一种双特异性抗体 | |
| KR20250152073A (ko) | 항체, 항원 결합 단편 및 사용 방법 | |
| CN109414489B (zh) | 网蛋白-1结合抗体及其用途 | |
| CN116249547B (zh) | 脑特异性血管生成抑制剂1(bai1)抗体及其用途 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| CN112969715A (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
| JP2024516621A5 (cg-RX-API-DMAC7.html) | ||
| CN111246881A (zh) | Pd-1抗体用于治疗肿瘤的用途 | |
| JP7808831B2 (ja) | 抗cd26抗体とその応用 | |
| JP2024536358A5 (cg-RX-API-DMAC7.html) | ||
| WO2024131846A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| WO2025146161A1 (en) | Antibody, antigen-binding fragment and medical use thereof |